|
| | Patients | Regimen | Outcome |
|
| Locke et al. (2009) [5] | 20-yo male
Bone marrow transplant
Positive DSA
Positive crossmatch | 1 dose (600 mg) | Improvement in allograft function and AMR resolution in biopsy |
|
| Lonze et al. (2010) [6] | 43-yo female
Kidney pair exchange
Positive DSA
Positive crossmatch | 8 doses (1200 mg × 4, 600 mg × 4) | Normalization of allograft function |
|
| González-Roncero et al. (2012) [7] | 2 cases
49-yo male and 34 yo female
Low immunological risk | 1 dose (600 mg) | Improvement in allograft function |
|
| Noone et al. (2012) [8] | 13-yo female
High immunological risk
Factor H deficiency | 2 doses (600 mg, 900 mg) | Improvement in allograft function |
|
| Stewart et al. (2012) [9] | 29-yo male
ABO incompatibility | 5 doses | Improvement in allograft function and resolution of AMR in biopsy |
|
| Kocak et al. (2013) [10] | 2 cases
26-yo female and 46-yo female
Positive DSA | 5 doses (5 × 900 mg) | Improvement in allograft function (only 1 recipient) |
|
| Burbach et al. (2014) [12] | 2 cases
43-yo female and 36-yo male
Positive DSA
Negative C4d in biopsy | 6 doses (900 mg × 4, 1200 mg × 2) | No improvement in allograft function |
|
| Chehade et al. (2015) [11] | 7-yo male
Positive DSA | 2 doses (600 mg × 2) | Normalization of allograft function |
|
| Current case (2015) | 50-yo female
Pretransplant positive DSA
Negative C4d in biopsy | 3 doses (1200 mg × 1, 900 mg × 2) | Transient stabilization of allograft function
Persistence of AMR in repeated biopsy |
|
